Compare · ELOX vs ZYME
ELOX vs ZYME
Side-by-side comparison of Eloxx Pharmaceuticals Inc. (ELOX) and Zymeworks Inc. (ZYME): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ELOX focuses on Biotechnology: Biological Products (No Diagnostic Substances), while ZYME focuses on Biotechnology: Pharmaceutical Preparations.
- ZYME is the larger of the two at $393.4M, about 9.9x ELOX ($39.7M).
- Both names hit the wire about 6 times in the past 4 weeks.
- ZYME has more recent analyst coverage (25 ratings vs 4 for ELOX).
- Company
- Eloxx Pharmaceuticals Inc.
- Zymeworks Inc.
- Price
- $3.99-4.55%
- $24.34+0.83%
- Market cap
- $39.7M
- $393.4M
- 1M return
- -
- -9.04%
- 1Y return
- -
- +99.18%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 6
- Recent ratings
- 4
- 25
Eloxx Pharmaceuticals Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Latest ELOX
- SEC Form 8-A12B filed by Eloxx Pharmaceuticals Inc.
- Amendment: SEC Form S-1/A filed by Eloxx Pharmaceuticals Inc.
- Eloxx Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
- SEC Form 3 filed by new insider Webster Stephen W
- SEC Form 3 filed by new insider Kjellson Nina S
- Large owner Coastlands Capital Lp disposed of 1,250,000 shares (SEC Form 4)
- Director Rubin Steven D converted options into 1,875 shares, increasing direct ownership by 15% to 14,625 units (SEC Form 4)
- President and CEO Aggarwal Sumit exercised 472,826 shares at a strike of $0.08 and was granted 1,000,000 shares, increasing direct ownership by 737% to 1,672,756 units (SEC Form 4)
- Director Walts Alan Edmund converted options into 1,875 shares, increasing direct ownership by 14% to 15,567 units (SEC Form 4)
- SEC Form DEF 14C filed by Eloxx Pharmaceuticals Inc.
Latest ZYME
- SEC Form 4 filed by EVP, General Counsel Schneider Paul R
- New insider Schneider Paul R claimed no ownership of stock in the company (SEC Form 3)
- Amendment: SEC Form SCHEDULE 13G/A filed by Zymeworks Inc.
- Zymeworks Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
- Zymeworks Announces Participation in Upcoming Investor Conferences
- SEC Form 10-Q filed by Zymeworks Inc.
- Zymeworks Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
- Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026